Incyte’s Targeted Drug Plus Chemo Shows Durable Tumor Shrinkage in Pancreatic Cancer, ESMO Data Reveal

Incyte’s investigational targeted therapy, combined with standard chemotherapy, produced lasting tumor responses in a subset of patients with advanced pancreatic cancer, according to new data presented at the European Society for Medical Oncology (ESMO) congress. The findings, reported by STAT+, highlight a potential new approach for a notoriously difficult-to-treat malignancy where progress has been slow. While the company did not specify the exact number of responders in the public statement, the durability of responses suggests the drug—whose mechanism was not detailed—may offer meaningful clinical benefit for patients who have exhausted other options. Pancreatic cancer remains one of the deadliest cancers, with a five-year survival rate of about 12%, underscoring the urgent need for novel therapies. Incyte’s results, though early, could position the company as a contender in the pancreatic cancer space, which has seen limited breakthroughs beyond chemotherapy and PARP inhibitors for select patients. If confirmed in larger trials, this combination could redefine treatment for a patient population with few alternatives. The next step will be to see whether these responses translate into improved overall survival—a high bar in this aggressive disease.